5 Biotech Stocks to Buy in 2025 Amid Uncertain Macroenvironment

By Ekta Bagri | July 02, 2025, 9:28 AM

Immunocore Holdings plc ADR

Kiniksa Pharmaceuticals International Plc

Verona Pharma Plc ADR

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

Exelixis, Inc. (EXEL): Free Stock Analysis Report

Alkermes plc (ALKS): Free Stock Analysis Report

Verona Pharma PLC American Depositary Share (VRNA): Free Stock Analysis Report

Kiniksa Pharmaceuticals International, plc (KNSA): Free Stock Analysis Report

Immunocore Holdings PLC Sponsored ADR (IMCR): Free Stock Analysis Report

This article originally published on Zacks Investment Research (zacks.com).

Zacks Investment Research

Mentioned In This Article

Immunocore Holdings plc ADR

Kiniksa Pharmaceuticals International Plc

Verona Pharma Plc ADR

Latest News

8 hours	EXEL or ARGX: Which Is the Better Value Stock Right Now? EXEL Zacks
10 hours	Novartis' Cosentyx Misses Primary Goal in Arteritis Phase III Study VRNA IMCR Zacks
11 hours	Zacks Industry Outlook Highlights Exelixis, Verona Pharma, Alkermes, Kiniska Pharmaceuticals and Immunocore EXEL VRNA KNSA ALKS Zacks
Jul-02	Kiniksa Pharmaceuticals: A 7.9 Score and Room for Growth KNSA Motley Fool
Jul-02	Apellis Stock Rises on $300M Royalty Deal With Sobi for Aspaveli IMCR VRNA Zacks
Jul-02	Wall Street Analysts Predict a 25.99% Upside in Verona Pharma (VRNA): Here's What You Should Know VRNA Zacks
Jul-02	5 Biotech Stocks to Buy in 2025 Amid Uncertain Macroenvironment EXEL ALKS IMCR KNSA VRNA Zacks
Jul-02	Vertex Gets EU Nod for New Cystic Fibrosis Drug Alyftrek EXEL Zacks
Jul-02	What's Fueling Tempus AI's Explosive Sales Growth? EXEL Zacks
Jul-01	Heart Drug Stock Rockets 20% On Sales, Boosts Outlook; Regeneron Pharma's Global Partnership Strong Tailwind KNSA Investor's Business Daily
Jul-01	Heart Drug Stock Rockets 20% On Sales, Boosts Outlook; Regeneron Pharma's Global Partnership Is Strong Tailwind KNSA Investor's Business Daily
Jul-01	RCKT's IND for RP-A701 in Dilated Cardiomyopathy Gets FDA Clearance EXEL Zacks
Jul-01	ALKS or CSLLY: Which Is the Better Value Stock Right Now? ALKS Zacks
Jul-01	Biogen Begins Phase III Felzartamab Study for Third Kidney Disease VRNA IMCR Zacks
Jul-01	ABBV to Boost Immunology Pipeline With Capstan Buyout for $2.1B EXEL Zacks